Targeting of metabotropic glutamate receptors for the treatment of schizophrenia

Current Pharmaceutical Design

Volumn 17, Issue 2, 2011, Pages 94-102

  Chaki, Shigeyuki ^a   Hikichi, Hirohiko ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antipsychotic; MGlu1 receptor; mGlu2 3 receptor; Schizophrenia

Indexed keywords

1 AMINO 1,5 INDANDICARBOXYLIC ACID; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 CYCLOPROPYL 5 [1 (2 FLUORO 3 PYRIDINYL) 5 METHYL 1H 1,2,3 TRIAZOL 4 YL] 2,3 DIHYDRO 1H ISOINDOL 1 ONE; 3 ETHYL 2 METHYL QUINOLIN 6 YL (4 METHOXY CYCLOHEXYL)METHANONE METHANESULFONATE; 4 [1 (2 FLUOROPYRIDINE 3 YL) 5 METHYL 1H 1,2,3 TRIAZOL 4 YL]N ISOPROPYL N METHYL 3,6 DIHYDROPYRIDINE 1(2H)CARBOXAMIDE; 4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 CARBOXY 2 METHYLPHENYLGLYCINE; 9 DIMETHYLAMINO 3 (N HEXA METHYLENEIMINYL) 3H 5 THIA 1,3,6 TRIAZAFLUOREN ONE; A 841720; BAY 367620; CLOZAPINE; EGLUMETAD; LY 487379; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 1 ANTAGONIST; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 2 AGONIST; METABOTROPIC RECEPTOR 2 POTENTIATOR; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 3 AGONIST; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MGS 0008; MGS 0028; OLANZAPINE; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; IC 50; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; GLUTAMIC ACID; HUMANS; MICE; MOLECULAR TARGETED THERAPY; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 79953311403     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795049570     Document Type: Article

References (98)

1. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995; 346: 477-81.
2. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67: e12.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
4. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3.
5. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-9.
6. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1159-72.
7. Tamminga CA. Schizophrenia and glutamate transmission. Crit Rev Neurobiol 1998; 12: 21-36.
8. Javitt DC. Glutamate receptors and schizophrenia: opportunities and caveats. Mol Psychiatry 1996; 1: 16-7.
9. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-82.
10. Toru M, Kurumaji A, Kumashiro S, Suga I, Takashima M, Nishikawa T. Excitatory amino acidergic neurons in chronic schizophrenic brain. Mol Neuropharmacol 1992; 2: 241-3.
11. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991; 148: 1301-8.
12. Halberstadt AL. The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol 1995; 18: 237-49.
13. Steinpreis PE. The behavioral and neurochemical effects of phencyclidine in humans and animals: Some implications for modeling psychosis. Behavioral Brain Res 1996; 74: 45-55.
14. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992; 258: 597-603.
15. Nakanishi S, Masu M. Molecular diversity and functions of glutamate receptors. Ann Rev Biophys Biomol Struct 1994; 23: 319-48.
16. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and fuctions. J Neurochem 1992; 58: 1184-6.
17. Schoepp DD, Conn PJ. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 1993; 14: 13-20.
18. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Ann Rev Pharmacol Toxicol 1997; 37: 205-37.
19. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 1993; 53: 1009-18.
20. Tanabe Y, Nomura A, Masu M, et al. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci 1993; 13: 1372-8.
21. Neki A, Ohishi H, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N. Preand postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody. Neurosci Lett 1996; 202: 197-200.
22. Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry 2009; 166: 812-20.
23. González-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008; 452: 93-7.
24. Chen Q, He G, Chen Q, et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 2005; 73: 21-6.
25. Egan MF, Straub RE, Goldberg TE, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004; 101: 12604-9.
26. Fujii Y, Shibata H, Kikuta R, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2003; 13: 71-6.
27. Sartorius LJ, Weinberger DR, Hyde TM, Harrison PJ, Kleinman JE, Lipska BK. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology 2008; 33: 2626-34.
28. Nakazato A, Kumagai T, Sakagami K, et al. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J Med Chem 2000; 43: 4893-909.
29. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic rceptor agonists in rats. Science 1998; 281: 1349-52.
30. Cartmell J, Monn J, Schoepp DD. Attenuation of specific PCPevoked behaviors by the potent mGluR2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 2000; 148: 423-9.
31. Galici R, Echemendia NG, Rodriguez AL, Conn PJ. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 2005; 315: 1181-7.
32. Rorick-Kehn LM, Johnson BG, Knitowski KM, et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007; 193: 121-36.
33. Takamori K, Hirota S, Chaki S, Tanaka M. Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat. Life Sci 2003; 73: 1721-8.
34. Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxyli c acid (LY404039). J Pharmacol Exp Ther 2008; 326: 209-17.
35. Schlumberger C, Schäfer D, Barberi C, et al. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol 2009; 20: 56-66.
36. Higgins GA, Ballard TM, Kew JN, et al. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 2004; 46: 907-17.
37. Shimazaki T, Kaku A, Chaki S. Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur J Pharmacol 2007; 575: 94-7.
38. Harich S, Gross G, Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 2007; 192: 511-9.
39. Jones CA, Brown AM, Auer DP, Fone KC. The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology (Berl) 2010; [Epub ahead of print].
40. Hackler EA, Byun NE, Jones CK, et al. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience 2010; 168: 209-18.
41. Nikiforuk A, Popik P, Drescher KU, et al. Effects of a positive allosteric modulator of mGlu2 receptors LY487379 on cognitive flexibility and impulsive-like responding in rats. J Pharmacol Exp Ther 2010; 335: 665-73.
42. Imre G, Fokkema DS, Ter Horst GJ. Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats. Eur J Pharmacol 2006; 544: 77-81.
43. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13: 1102-7.
44. Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005; 179: 303-9.
45. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003; 117: 697-706.
46. Calcagno E, Carli M, Baviera M, Invernizzi RW. Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J Neurochem 2009; 108: 521-32.
47. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 2006; 63: 1372-6.
48. Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2009; 30: 25-31.
49. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008; 33: 1690-703.
50. Greenslade RG, Mitchell SN. Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology 2004; 47: 1-8.
51. Karasawa J, Yoshimizu T, Chaki S. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci Lett 2006; 393: 127-30.
52. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 2001; 40: 847-55.
53. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 2000; 292: 76-87.
54. Gewirtz JC, Marek GJ. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 2000; 23: 569-76.
55. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 2007; 72: 477-84.
56. Aronica E, Gorter JA, Ijlst-Keizers H, et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci 2003; 17: 2106-18.
57. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 1998; 18: 9594-600.
58. Neale JH, Bzdega T, Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000; 75: 443-52.
59. Olszewski RT, Wegorzewska MM, Monteiro AC, et al. Phencyclidine and dizocilpine induced behaviors reduced by Nacetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry 2008; 63: 86-91.
60. Fricker AC, Mok MH, de la Flor R, et al. Effects of Nacetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 2009; 56: 1060-7.
61. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995; 34: 1-26.
62. Shigemoto R, Nakanishi S, Mizuno N. Distribution of the Mrna for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol 1992; 322: 121-35.
63. Martin LJ, Blackstone CD, Huganir RL, Price DL. Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 1992; 9: 259-70.
64. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, David KL, Meador-Woodruff JH. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005; 57: 123-31.
65. Bunney WE, Bunney BG. Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Brain Res Rev 2000; 31: 138-46.
66. Weinberger DR, Egan MF, Bertolino A, et al. Goldberg TE. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50: 825-44.
67. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. Metabotropic glutamate receptors mRNA expression in the schizophrenic thalamus. Biol Psychiatry 1999; 47: 22-8.
68. Chowdari KV, Mirnics K, Semwal P, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002; 11: 1373-80.
69. Erdely HA, Tamminga CA, Roberts RC, Vogel MW. Regional alterations in RGS4 protein in schizophrenia. Synapse 2006; 59: 472-9.
70. Volk DW, Eggan SM, Lewis DA. Alterations in metabotropic glutamate receptor 1{alpha} and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry 2010; 167: 1489-98.
71. De Vry J, Horváth E, Schreiber R. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu1 receptor antagonist BAY 36-7620. Eur J Pharmacol 2001; 428: 203-14.
72. Satow A, Maehara S, Ise S, et al. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-nisopropyl -N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. J Pharmacol Exp Ther 2008; 326: 577-86.
73. Satow A, Suzuki G, Maehara S, et al. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1, 2, 3,-triazole-4-yl]-2, 3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther 2009; 330: 179-90.
74. Hikichi H, Nishino M, Fukushima M, et al. Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice. Eur J Pharmacol 2010; 639: 99-105.
75. Brody SA, Conquet F, Geyer MA. Disruption of prepulse inhibition in mice lacking mGluR1. Eur J Neurosci 2003; 18: 3361-6.
76. Mao L, Conquet F, Wang JQ. Augmented motor activity and reduced striatal preprodynorphin mRNA induction in response to acute amphetamine administration in metabotropic glutamate receptor 1 knockout mice. Neuroscience 2001; 106: 303-12.
77. Aiba A, Kano M, Chen C, et al. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 1994; 79: 377-88.
78. Conquet F, Bashir ZI, Davies CH, et al. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature 1994; 372: 237-43.
79. Grauer SM, Marquis KL. Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology 1999; 141: 405-12.
80. Pietraszek M, Gravius A, Schäfer D, Weil T, Trifanova D, Danysz W. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 2005; 49: 73-85.
81. El-Kouhen O, Lehto SG, Pan JB, et al. Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol 2006; 149: 761-74.
82. Schröder UH, Müller T, Schreiber R, et al. The potent noncompetitive mGlu1 receptor antagonist BAY 36-7620 differentially affects synaptic plasticity in area cornu ammonis 1 of rat hippocampal slices and impairs acquisition in the water maze task in mice. Neuroscience 2008; 157: 385-95.
83. Benquet P, Gee CE, Gerber U. Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J Neurosci 2002; 22: 9679-86.
84. Heidinger V, Manzerra P, Wang XQ, et al. Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J Neurosci 2002; 22: 5452-61.
85. Melendez RI, Vuthiganon J, Kalivas PW. Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. J Pharmacol Exp Ther 2005; 314: 139-47.
86. Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest 2009; 119: 706-16.
87. Galante M, Diana MA. Group I metabotropic glutamate receptors inhibit GABA release at interneuron-Purkinje cell synapses through endocannabinoid production. J Neurosci 2004; 24: 4865-74.
88. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 2001; 31: 463-475.
89. Varma N, Carlson GC, Ledent C, Alger BE. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci 2001; 21: RC188.
90. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009; 89: 309-80.
91. Muly EC, Maddox M, Smith Y. Distribution of mGluR1alpha and mGluR5 immunolabeling in primate prefrontal cortex. J Comp Neurol 2003; 467: 521-35.
92. Paspalas CD, Selemon LD, Arnsten AF. Mapping the regulator of G protein signaling 4 (RGS4): presynaptic and postsynaptic substrates for neuroregulation in prefrontal cortex. Cereb Cortex 2009; 19: 2145-55.
93. López-Bendito G, Shigemoto R, Fairén A, Luján R. Differential distribution of group I and metabotropic glutamate receptors during rat cortical development. Cereb Cortex 2002; 12: 625-38.
94. Baude A, Nusser Z, Roberts JD, Mulvihill E, McIlhinney RA, Somogyi P. The metabotropic glutamate receptor (mGluR1alpha) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction. Neuron 1993; 11: 771-87.
95. Rorick-Kehn LM, Johnson BG, Burkey JL, et al. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxyl ic acid (LY404039). J Pharmacol Exp Ther 2007; 321: 308-17.
96. Monn JA, Valli MJ, Massey SM, et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 1999; 42: 1027-40.
97. Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999; 291: 161-70.
98. Suzuki G, Kimura T, Satow A, et al. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl- N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther 2008; 321: 1144-53.